Tourmaline Bio, Inc. stock is up 20.81% since 30 days ago. The next earnings date is Dec 12, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 November’s closed higher than October. 100% of analysts rate it a buy.
Talaris Therapeutics, Inc. engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases. Its lead product candidate is FCR001, which is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants.